Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of “Hold” by Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given an average rating of “Hold” by the ten ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $5.4286.

Several research firms have issued reports on GOSS. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Barclays lowered shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. Oppenheimer lowered their price objective on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th.

Gossamer Bio Price Performance

GOSS opened at $0.37 on Friday. The stock’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $2.29. The firm has a market cap of $86.84 million, a price-to-earnings ratio of -0.49 and a beta of 2.16. Gossamer Bio has a 1 year low of $0.32 and a 1 year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $7.53 million. As a group, sell-side analysts anticipate that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Trading of Gossamer Bio

Institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. grew its position in shares of Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock valued at $189,000 after purchasing an additional 50,666 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares in the last quarter. Invesco Ltd. boosted its stake in Gossamer Bio by 36.0% during the fourth quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock valued at $1,485,000 after buying an additional 126,823 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Gossamer Bio by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after buying an additional 8,239 shares during the last quarter. Finally, Beacon Pointe Advisors LLC purchased a new position in Gossamer Bio during the 4th quarter valued at approximately $34,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

More Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Neutral Sentiment: Faruqi & Faruqi issued a deadline alert reminding GOSS investors of a June 1, 2026 deadline to participate in securities‑class action proceedings (procedural timing information for potential plaintiffs). GOSS Deadline Alert
• Negative Sentiment: Robbins LLP reminded investors that a class action has been filed on behalf of purchasers of GOSS securities between June 16, 2025 and Feb 20, 2026, signaling expanding plaintiff interest. GOSS Stockholder Alert: Robbins LLP
• Negative Sentiment: Multiple law firms (Schall Law Firm, Bronstein Gewirtz & Grossman, Gainey McKenna & Egleston, Bragar Eagel & Squire, Holzer & Holzer, Levi & Korsinsky and others) have announced or are soliciting lead plaintiffs and claims against Gossamer, increasing litigation momentum and potential aggregate exposure. Examples: Schall Law Firm notice. Schall Law Firm Notice
• Negative Sentiment: Bronstein, Gewirtz & Grossman and Gainey McKenna & Egleston announced class action filings covering the same June 16, 2025–Feb 20, 2026 class period, suggesting overlapping suits that could consolidate and raise litigation costs. Bronstein Notice
• Negative Sentiment: Holzer & Holzer’s investor alert alleges defendants made false/misleading statements and failed to disclose material adverse facts about PROSERA’s study design—specifically concerns about controlling for placebo response at Latin American sites—providing a specific factual theory for damages. Holzer & Holzer Investor Alert
• Negative Sentiment: Levi & Korsinsky and other firms tie the current litigation wave to the company’s Phase 3 PROSERA miss (company missed the primary endpoint and previously provided forward‑looking guidance that plaintiffs say omitted a heightened statistical threshold), which remains the root cause of the share plunge and ensuing suits. PROSERA Topline Results / Levi & Korsinsky
• Negative Sentiment: Local outlets note additional firm filings (Gainey, Bragar, Gainey McKenna & Egleston), amplifying negative headlines and likely increasing short‑term volatility and selling pressure as investors weigh legal risk and dilution potential. Bragar Eagel & Squire Notice

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.